Canaccord lowered the firm’s price target on Insulet to $175 from $355 and keeps a Buy rating on the shares. The firm said they delivered impressive results in Q3, beating revenue estimates and raising FY/23 US revenue guidance, with upside driven by continued strength across the business with strong new patient starts both US and globally but the target was lowered due to lower comps.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PODD:
- Early notable gainers among liquid option names on November 3rd
- Insulet raises FY23 revenue growth view to 26%-27% form 22%-25%
- Insulet sees Q4 revenue growth 22%-25%, consensus $456.14M
- Insulet reports Q3 adjusted EPS 71c, consensus 40c
- Notable companies reporting after market close
Questions or Comments about the article? Write to editor@tipranks.com